The VEGF x PD-(L)1 pipeline is growing and TNBC may benefit

In the rapidly expanding PD-L1 x VEGF bispecifics revolution, BioNTech is making a play in triple-negative breast cancer with newly acquired BNT327. It hasn’t tested the bispecific head-to-head against standard PD-1 blockers, but a first look at overall survival results suggests an advantage.

At the San Antonio Breast Cancer Symposium (SABCS) this week, academic researchers from Fudan University and other Chinese institutions presented updated data from a Phase II trial sponsored by Biotheus Inc. showing that BNT327 (formerly PB8002) led to 13.5 months of progression-free survival (PFS) when combined with nab-paclitaxel as first-line therapy for locally advanced or metastatic TNBC. ...